Amelioration of user experiences and glycaemic outcomes with an Advanced Hybrid Closed Loop System in a real-world clinical setting

Beato-Víbora, Pilar Isabel; Gallego-Gamero, Fabiola; Ambrojo-López, Ana; Gil-Poch, Estela; Martín-Romo, Irene; Arroyo-Díez, Francisco Javier

doi:10.1016/j.diabres.2021.108986

Cited by 35 publications

(24 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No difference in time in hypoglycemia < 70 or 54 mg/dl were seen at 2 weeks or 1 month. The real-world benefits of the Medtronic 780G system in terms of glycemic control were maintained after 3 months of use of the system ( 20 ). These data agree with previous trials of the Minimed 780 G system ( 17 , 19 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Comparison of Two Hybrid Closed-Loop Systems in Italian Children and Adults With Type 1 Diabetes

et al. 2022

View full text Add to dashboard Cite

Tandem Control-IQ and Minimed 780G represent the most Advanced Hybrid Closed Loop (AHCL) systems currently available in pediatric and adult subjects with Type 1 Diabetes (T1D). We retrospectively compared clinical and continuous glucose monitoring data from 51 patients who upgraded to Minimed 780G system and have completed 1-month observation period with data from 39 patients who upgraded to Tandem Control-IQ. Inverse probability weighting was used to minimize the basal characteristics imbalances. Both AHCL systems showed a significant improvement in glycemic parameters. Minimed 780G group achieved higher TIR increase (p= 0.004) and greater reduction of blood glucose average (p= 0.001). Tandem Control-IQ system significantly reduced the occurrence of TBR (p= 0.010) and the Coefficient of Variation of glucose levels (p= 0.005). The use of ACHL systems led to a significant improvement of glycemic control substantially reaching the International recommended glycemic targets. Minimed 780G appears to be more effective in managing hyperglycemia, while Tandem Control-IQ seems to be more effective in reducing time in hypoglycemia.

show abstract

Section: Discussionmentioning

confidence: 99%

“…These findings are supported by other evidence that demonstrates safety and effectiveness in controlling day and night glucose levels ( 17 – 19 ). The real-world use of Minimed 780G also provides an increased level of patient satisfaction ( 20 ).…”

Section: Introductionmentioning

confidence: 99%

A Comparison of Two Hybrid Closed-Loop Systems in Italian Children and Adults With Type 1 Diabetes

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Subsequent real-world studies confirmed the greater effectiveness of Minimed 780G compared to HCL (Minimed 670G), PLGS (Minimed 640G) and multi-injection therapy in patients with T1D [ 21 , 22 , 23 ]. The use of the Minimed 780G system led to a reduction of time above range (TAR > 180 mg/dL) without increasing time below range (TBR < 70 mg/dL) in 52 patients (aged 15–65 years), that were well-controlled and experienced Minimed 640 users [ 21 ].…”

Section: Aid Systemsmentioning

confidence: 97%

Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023

Bassi

Franzone

Dufour

et al. 2023

Life

View full text Add to dashboard Cite

Type 1 diabetes (T1D) patients’ lifestyle and prognosis has remarkably changed over the years, especially after the introduction of insulin pumps, in particular advanced hybrid closed loop systems (AHCL). Emerging data in literature continuously confirm the improvement of glycemic control thanks to the technological evolution taking place in this disease. As stated in previous literature, T1D patients are seen to be more satisfied thanks to the use of these devices that ameliorate not only their health but their daily life routine as well. Limited findings regarding the use of new devices in different age groups and types of patients is their major limit. This review aims to highlight the main characteristics of each Automated Insulin Delivery (AID) system available for patients affected by Type 1 Diabetes Mellitus. Our main goal was to particularly focus on these systems’ efficacy and use in different age groups and populations (i.e., children, pregnant women). Recent studies are emerging that demonstrate their efficacy and safety in younger patients and other forms of diabetes.

show abstract

“…Glycaemic outcomes were comparable to randomised clinical trials performed under controlled conditions 5,6 and observational studies reported in other countries. [7][8][9] However, most studies have only reported outcomes for a specific clinically approved HCL system, rather than multiple systems as commonly observed in clinical practice. Improvements in glycaemic control were observed within 5 months at the first clinic follow-up visit and extended to subsequent follow-up at 9 months.…”

Section: Real World Effectiveness Of Clinically Approved Hybrid Close...mentioning

confidence: 99%

Real world effectiveness of clinically approved hybrid closed loop systems in a UK Secondary Care Diabetes Service

Bashir

Elisaus

Chatzimavridou-Grigoriadou

et al. 2022

Diabet Med

View full text Add to dashboard Cite

Amelioration of user experiences and glycaemic outcomes with an Advanced Hybrid Closed Loop System in a real-world clinical setting

Cited by 35 publications

References 41 publications

A Comparison of Two Hybrid Closed-Loop Systems in Italian Children and Adults With Type 1 Diabetes

A Comparison of Two Hybrid Closed-Loop Systems in Italian Children and Adults With Type 1 Diabetes

Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023

Real world effectiveness of clinically approved hybrid closed loop systems in a UK Secondary Care Diabetes Service

Contact Info

Product

Resources

About